EUVIMEDEUVIMED entdecken
Open Access

Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer

Ke Xin Yee, Yu-Cheng Lee, Hieu Duc Nguyen, Ming-Yao Chen, Yi-Chun Ni, Yung-Fu Wu, Kuen-Haur Lee

American Journal of Cancer Research · 2024 · 14 (9) · 4353-4366

DOI: 10.62347/lude7524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Cancer Research, 2024. Verfasst von Ke Xin Yee und 6 weiteren Autor:innen. Beteiligte Einrichtung: PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University-Shuang Ho Campus Ne…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer is an aggressive cancer with silent symptoms and high mortality with less than 11% of the 5-year survival rate. Until now, the significance of genes as clinical biomarkers in the early stages of pancreatic cancer has not been fully understood. Hence, this study aims to reveal the significant genes in the early stages of pancreatic cancer using bioinformatic analysis and in vitro experiments, and to serve as clinical biomarkers for early detection. We used Cancer RNA-Seq Nexus database and identified one tumor suppressor gene (NAGK), and five oncogenes (FXYD3, ACTR1A, B3GNT3, SIGIRR, and EXOC1) that are significant in the early stages of pancreatic cancer. The expression of NAGK, FXYD3, ACTR1A, B3GNT3, SIGIRR, and EXOC1 were determined from the GEPIA, UALCAN, and HPA database. It has been shown that pancreatic cancer tumor dissemination is an event that can occur in early lesions, rather than being solely restricted in the developed primary tumor. Thus, the six hub genes that were differentially expressed between stage I and stage II of primary pancreatic cancer tumors were compared to metastasis-related genes (1938 genes) in the human cancer metastasis database (HCMDB), yielding two overlapped genes (B3GNT3 and FXYD3). To establish the expression correlation between these two specific genes with metastatic characteristics of the early stage of pancreatic cancer and migratory ability in pancreatic cancer cell lines, the expression patterns of B3GNT3 and FXYD3 were examined in four different migratory abilities of pancreatic cancer cell lines, including HPAC, BxPC-3, AsPC-1, and PANC-1, as well as the normal pancreatic duct epithelial cell line HPDE6-C7. The results displayed that the expression of the FXYD3 gene was dramatically increased with the migratory ability enhanced of four pancreatic cancer cell lines. Thus, in the follow-up study, we will demonstrate the functional role of FXYD3 in pancreatic cancer tumorigenesis. This study revealed that the FXYD3 may act as a significant oncogene in the early stage of pancreatic cancer.

Schlagwörter

Stichwörter der Autor:innen

FXYD3Pancreatic cancerbiomarkerearly stagesmetastasis

Autor:innen und Institutionen

  • PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University-Shuang Ho Campus New Taipei 235, Taiwan.
  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University Taipei 11031, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Taipei Medical University Taipei 110, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Shuang Ho Hospital Ministry of Health and Welfare New Taipei 235, Taiwan.
  • Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center Taipei 114, Taiwan.
  • TMU Research Center for Digestive Medicine, Taipei Medical University Taipei 110, Taiwan.

Zitieren

APA

Yee, K. X., Lee, Y. C., Nguyen, H. D., Chen, M. Y., Ni, Y. C., Wu, Y. F., & Lee, K. H. (2024). Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer. American Journal of Cancer Research, 14(9), 4353-4366. https://doi.org/10.62347/lude7524

Vancouver

Yee KX, Lee YC, Nguyen HD, Chen MY, Ni YC, Wu YF, et al. Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer. American Journal of Cancer Research. 2024;14(9):4353-4366. doi:10.62347/lude7524

BibTeX
@article{Yee2024,
  author = {Yee, Ke Xin and Lee, Yu-Cheng and Nguyen, Hieu Duc and Chen, Ming-Yao and Ni, Yi-Chun and Wu, Yung-Fu and Lee, Kuen-Haur},
  title = {Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer},
  journal = {American Journal of Cancer Research},
  year = {2024},
  volume = {14},
  number = {9},
  pages = {4353--4366},
  doi = {10.62347/lude7524}
}
Kostenlos starten →